Alentis Therapeutics is developing breakthrough treatments for fibrotic and rare diseases and associated cancers. The company’s lead candidates are monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1 (CLDN1). Non-junctional CLDN1 is a previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver, kidney, lung fibrosis, and solid tumors.
Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.